Central sensitization
What it means for the nervous system to turn the volume up, and how it is studied.
For a long time clinicians sorted pain into two boxes. Nociceptive pain comes from injured or inflamed tissue, like a sprained ankle or an arthritic knee. Neuropathic pain comes from damage to the nerves themselves. But many people with chronic pain fit neither box: widespread or intense pain, unremarkable scans, and treatments aimed at tissues or nerves that helped little. In 2021 the pain research community gave that group a name.
What is nociplastic pain?
Nociplastic pain is the IASP's name for pain that arises from altered pain processing in the nervous system without clear tissue damage or nerve injury. Described as a mechanistically distinct third category in a 2021 Lancet review, it is often widespread, more intense than any visible problem explains, and responds less well to treatments aimed at tissues, such as anti-inflammatories, injections or surgery.
It is real pain produced by a real nervous system. The label describes what is driving it, and it points treatment toward the nervous system rather than toward a structural cause that may not exist.
In their 2021 review in The Lancet, Mary-Ann Fitzcharles, Daniel Clauw and colleagues described nociplastic pain as a third category that is mechanistically distinct from the other two. Its mechanisms are not fully understood, but augmented pain and sensory processing in the central nervous system, along with altered pain modulation, are thought to play the leading roles.
People with nociplastic pain often report pain in several body regions, pain that is more intense than any visible tissue problem would explain, and other symptoms that seem to come from the central nervous system: fatigue, poor sleep, memory difficulties and mood changes. Nociplastic pain can occur on its own, as in fibromyalgia or tension-type headache, or mixed with nociceptive or neuropathic pain, as often happens in chronic low back pain.
The practical point the authors emphasized is the one that changes treatment. Nociplastic pain tends to respond less well to treatments aimed at the periphery, such as anti-inflammatory drugs, opioids, surgery or injections.
Naming a category is only useful if clinicians can identify it. In 2021, Eva Kosek and colleagues proposed clinical criteria and a grading system for chronic nociplastic pain affecting the musculoskeletal system (Kosek et al., 2021). The criteria weigh the duration and distribution of pain, the absence of a sufficient nociceptive or neuropathic explanation, signs of pain hypersensitivity, and associated symptoms such as sleep problems, fatigue and cognitive complaints.
In 2024, an international consensus group published recommendations specifically for classifying low back pain as nociceptive, neuropathic, nociplastic or mixed (Nijs et al., 2024). This kind of phenotyping is meant to match people with treatments that fit their dominant mechanism, rather than treating every back as if it had the same problem.
The terms travel together, but they are not the same thing. Central sensitization describes a state in which neurons in the spinal cord and brain become more responsive, so that ordinary input is amplified. Reviews have linked these states to neuroinflammation (Ji et al., 2018) and to changes in brain function and structure, immune processing and peripheral factors (Kaplan et al., 2024). People with nociplastic pain are often diffusely tender and can be more sensitive than others to non-painful stimuli such as light, odors and noise.
It is worth being careful here. Central sensitization is a neurophysiological concept, much of it studied in animals, and it is hard to measure directly in people. A 2024 critical review asked whether chronic pain is in fact caused by central sensitization and urged caution about treating the two terms as interchangeable (Velasco et al., 2024). Even the researchers who championed the nociplastic concept have written about where it needs to go next (Kosek et al., 2024).
Honest communication means acknowledging that the science is still developing. Nociplastic pain is a clinical description of a pattern; central sensitization is one proposed mechanism behind it. The first is observable at the bedside. The second is inferred.
If pain is being driven largely by changes in how the nervous system processes signals, it makes sense to choose treatments that target the nervous system and the person's relationship with their pain rather than the tissues. The approaches with the best support include:
Recognizing nociplastic features can also help clinicians and patients avoid an endless search for a structural cause, or repeated procedures that are unlikely to help. Our guide to chronic pain treatment lays out the options and the evidence behind each.
No. Telling someone their pain is central or nociplastic can be heard as "it's not real" or "it's in your head", and that is never the message. Nociplastic pain is real pain produced by a real nervous system. A useful framing for patients is that the alarm system has become more sensitive, and that sensitivity can often be turned down with the right combination of understanding, movement and support.
The concept is still being refined, and its relationship to central sensitization is debated. But it has already changed how clinicians think about treatment, steering care toward approaches that work with the nervous system rather than chasing causes that scans cannot find. Karuna's program is designed for exactly this kind of pain; see how it works.
Close. Nociplastic pain is the formal IASP term for pain arising from altered nervous system processing without tissue or nerve damage. Neuroplastic pain is a plainer-language name used by some clinicians and by this site for the same idea, with an emphasis on the fact that the processing is learned and can change. Our guide to neuroplastic pain covers it.
Fibromyalgia is the clearest example, along with tension-type headache and several conditions where pain persists without a tissue explanation. Nociplastic mechanisms also mix with nociceptive or neuropathic ones in common conditions such as chronic low back pain, which is why the 2024 consensus on back pain classification exists.
No single test confirms it. Diagnosis is clinical, using criteria such as those proposed by Kosek and colleagues: the duration and spread of pain, the absence of a sufficient nociceptive or neuropathic explanation, signs of hypersensitivity, and associated symptoms like fatigue, poor sleep and cognitive difficulty. Normal scans and bloodwork are expected rather than reassuring evidence that nothing is wrong.
Less well than for nociceptive pain. The Lancet review notes that nociplastic pain responds poorly to treatments aimed at the periphery, including anti-inflammatory drugs, opioids, surgery and injections. Some medications that act on the nervous system help some people modestly. Never change a medication without talking to whoever prescribed it.
It is widely proposed, not proven. Much of the underlying research is in animals, and it is hard to measure central sensitization directly in people. A 2024 critical review (Velasco et al.) questioned whether it causes chronic pain or accompanies it. The nociplastic label stands on the clinical pattern, which is observable, rather than on any one mechanism.
Talk with our care team about your pain, your history, and whether KVET™ is right for you. Free, and from the comfort of home.